Synapse - Dmitriy Zamarin

Results (28)

Phase IIa study of PLX2853 in gynecologic cancers with known ARID1A mutation and phase Ib/IIa study of PLX2853/carboplatin in platinum-resistant epithelial ovarian cancer

Journal Article

Duska, L. R.; Zamarin, D.; Hamilton, E.; Oza, A.; Fleming, G.; Spira, A.; Yeku, O. O.; Richardson, D. L.; Walling, J.; Inokuchi, K.; more...
JCO Precision Oncology (2023)

Fulltext@MSK | Save

CRI-CCTG-0003/IND.240: An immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC)

Meeting Abstract

Mackay, H.; Tinker, A.; Nelson, B.; Zamarin, D.; Odunsi, K.; Lheureux, S.; Ellard, S.; Smrke, A.; Gaudreau, P. O.; Faulkner, T.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Germline variants in non- BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival

Meeting Abstract

Kahn, R. M.; Selenica, P.; Boerner, T.; Xiao, Y.; Sia, T.; Sheehan, M.; Zhou, Q.; Iasonos, A.; Grisham, R. N.; O'Cearbhaill, R. E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

State of the biomarker dcience in ovarian cancer: A National Cancer Institute Clinical Trials Planning Meeting Report

Journal Article

Ethier, J. L.; Fuh, K. C.; Arend, R.; Konecny, G. E.; Konstantinopoulos, P. A.; Odunsi, K.; Swisher, E. M.; Kohn, E. C.; Zamarin, D.
JCO Precision Oncology (2022)

Fulltext@MSK | Save

Germline SMARCA4 deletion as a driver of uterine cancer: An atypical presentation

Journal Article

Navitski, A.; Al-Rawi, D. H.; Makker, V.; Weigelt, B.; Zamarin, D.; Liu, Y.; Arnold, A. G.; Chui, M. H.; Mandelker, D. L.; Walsh, M.; more...
JCO Precision Oncology (2022)

Fulltext@MSK | Save

Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results

Meeting Abstract

Zamarin, D.; Odunsi, K.; Zsiros, E.; Slomovitz, B. M.; Pimentel, A.; Duska, L. R.; Reilley, M.; Nemunaitis, J. J.; Hamouda, D. M.; Patel, H.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Cell-free DNA analysis as a molecular tool to monitor response to immune checkpoint inhibition in endometrial cancer

Meeting Abstract

Manning-Geist, B.; Patel, J. A. A.; Marra, A.; Da Cruz Paula, A.; Hanlon, E. J.; Abu-Rustum, N.; Shah, R. H.; Berger, M. F.; Hensley, M. L.; Zamarin, D.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)

Meeting Abstract

Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC)

Meeting Abstract

Grisham, R. N.; Li, K.; Zhou, Q.; Iasonos, A.; Girshman, J.; Shah, P.; Jang, D.; Kyi, C.; Cohen, S. M.; O'Cearbhaill, R. E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)

Meeting Abstract

Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save